Angioimmunoblastic T-lymphoma: overview, single centre experience and case report of the sequential development of difuse large B-cell lymphoma
Authors:
J. Michalka 1; A. Janíková 1; J. Soukup 2; M. Kalinová 2; L. Křen 3; Z. Král 1; M. Mayer 1
Authors‘ workplace:
Interní hematologická a onkologická klinika FN Brno a Lékařská fakulta Masarykovy univerzity v Brně
1; Ústav patologie a molekulární medicíny 2. lékařské fakulty Univerzity Karlovy a FN Motol
2; Ústav patologické anatomie FN Brno a Lékařská fakulta Masarykovy univerzity v Brně
3
Published in:
Transfuze Hematol. dnes,23, 2017, No. 4, p. 215-222.
Category:
Overview
Angioimmunoblastic T-cell lymphoma is a rare, aggressive lymphoproliferative disease that arises from T-cells derived from the germinal centre. It is usually diagnosed in advanced stages but B-symptoms, oedemas and various skin changes can occur as initial signs of the disease and may be even more significant than lymph node or organ involvement. These general symptoms can mask the lymphoma and delay diagnosis. Remarkably, a B-cell lymphoma may develop during the course of this disease, usually diffuse large B-cell lymphoma. In this article, we present a general overview, single centre experience from the past 16 years and a case report of diffuse large B-cell lymphoma occurring during the treatment of angioimmunoblastic T-cell lymphoma in a single patient.
Key words:
angioimmunoblastic T-cell lymphoma – diffuse large B-cell lymphoma – immunoblasts – EBV
Sources
1. Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimunoblastic T-cell lymphoma: analysis of the International Peripheral T-cell Lymphoma Project. J Clin Oncol 2013;31(2): 240–246.
2. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumours of hematopoietic and lymphoid tissues. Lyon, France, IARC Press, 2008.
3. Frizzera, G. Atypical lymphoproliferative disorders. In: Knowles DM, ed. Neoplastic hematopathology. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins;2001: 569–579.
4. Cortes JR, Palomero T. The curious origins of angioimmunoblastic T-cell lymphoma. Curr Opin Hematol 2016;23(4): 434–443.
5. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127: 2375–2390.
6. Attygalle AD, Kyriakou C, Dupuis J, et al. Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol 2007;31(7): 1077–1088.
7. Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood 2017;129(9): 1095–1102.
8. Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol 2003;121(5): 681–691.
9. Lachenal F, Berger F, Ghesquieres H, et al. Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. Medicine (Baltimore) 2007;86(5): 282–292.
10. Mourad N, Mounier N, Briere J, et al. Groupe d’Etude des Lymphomes de l’Adulte. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood 2008;111(9): 4463–4470.
11. Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 2010;151(2): 159–166.
12. Schetelig J, Fetscher S, Reichle A, et al. Longterm disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high dose chemotherapy and autologous stem cell transplantation. Haematologica 2003;88(11): 1272–1278.
13. Zelenetz AD, Hamlin P, Kewalramani T, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin‘s lymphoma. Ann Oncol 2003;14(suppl 1): i5–10.
14. Olivieri A, Brunori M, Capelli D, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004;72(1): 10–7.
15. Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004;101(8): 1835–1842.
16. Reboursiere E, Le Bras F, Herbaux C, et al. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget 2016;7(51): 85573–85583.
17. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013;31(16): 1970–1976.
18. Kyriakou C, Canals C, Finke J, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009;27(24): 3951–3958.
19. Advani R, Horwitz S, Zelenetz A, Horning SJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 2007;48(3): 521–525.
20. Huang J, Zhang PH, Gao YH, Qiu LG. Sequential development of diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. Diagn Cytopathol 2012;40(4): 346–351.
21. Ahearne MJ, Allchin RL, Fox CP, Wagner SD. Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. Br J Haematol 2014;166: 326–335.
22. Abruzzo LV, Schmidt K, Weiss LM, et al. B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. Blood 1993;82: 241–246.
23. Zettl A, Lee SS, Rudiger T, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 2002;117: 368–379.
24. Xu Y, McKenna RW, Hoang MP, Collins RH, Kroft SH. Composite angioimmunoblastic T-cell lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 2002;118: 848–854.
25. Wang Y, Xie B, Chen Y, et al. Development of angioimmunoblastic T-cell lymphoma after treatment of diffuse large B-cell lymphoma: a case report and review of literature. Int J Clin Exp Pathol 2014;7(6): 3432–3438.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2017 Issue 4
Most read in this issue
- Angioimmunoblastic T-lymphoma: overview, single centre experience and case report of the sequential development of difuse large B-cell lymphoma
- Next generation sequencing in acute myeloid leukaemia: new insights into the pathogenesis and development of leukemic clones
- Possible discontinuation of treatment by tyrosine kinase inhibitors in patients with chronic myeloid leukemia and concept of treatment-free remission
- The first oral proteasome inhibitor in the treatment of relapsed/refractory multiple myeloma